Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina

S Talwar, I B Squire, P F Downie, J E Davies, L L Ng

Abstract

Objective—To compare circulating concentrations of N terminal pro-brain natriuretic peptide (N-BNP) and cardiotrophin 1 in stable and unstable angina.

Design and setting—Observational study in a teaching hospital.

Patients—15 patients with unstable angina, 10 patients with stable angina, and 15 controls.

Main outcome measures—Resting plasma N-BNP and cardiotrophin 1 concentrations.

Results—N-BNP concentration (median (range)) was 714 fmol/ml (177–3217 fmol/ml) in unstable angina, 169.5 fmol/ml (105.7–399.5 fmol/ml) in stable angina ($p = 0.005$ *v* unstable angina), and 150.5 fmol/ml (104.7–236.9 fmol/ml) in controls ($p < 0.0001$ *v* unstable angina; NS *v* stable angina). Cardiotrophin 1 concentration was 142.5 fmol/ml (42.2–527.4 fmol/ml) in unstable angina, 73.2 fmol/ml (41.5–102.1 fmol/ml) in stable angina ($p < 0.05$ *v* unstable angina), and 27 fmol/ml (6.9–54.1 fmol/ml) in controls ($p < 0.0005$ *v* stable angina; $p < 0.0001$ *v* unstable angina). Log cardiotrophin 1 correlated with log N-BNP in unstable angina ($r = 0.93$, $p < 0.0001$).

Conclusions—Both circulating N-BNP and cardiotrophin 1 are raised in unstable angina, while cardiotrophin 1 alone is raised in stable angina. The role of cardiotrophin 1 and the relation between cardiotrophin 1 and N-BNP in myocardial ischaemia remain to be defined.

(Heart 2000;84:421–424)

Keywords: cardiotrophin 1; brain natriuretic peptide; angina pectoris

Cardiotrophin 1, a cytokine of the interleukin 6 (IL-6) family, induces cardiac hypertrophy through the Janus kinase/transcription 3 (JAK/STAT) cascade.¹ In addition cardiotrophin 1 has anti-apoptotic effects in myocytes,² mediated through mitogen activated protein kinase. Cardiotrophin 1 induces heat shock protein accumulation, protecting cultured cardiomyocytes from thermal or ischaemic stress.³

Brain natriuretic peptide (BNP) is synthesised predominantly in the left ventricle as the prohormone prepro-BNP.⁴ Plasma concentrations of N terminal proBNP (N-BNP or NTproBNP) are likely to reflect de novo synthesis rather than the release of stored BNP, and thus may better reflect natriuretic pathway activation. Raised BNP and N-BNP concentrations occur following myocardial infarction and are inversely related to prognosis.⁵ Plasma BNP⁶ and IL-6⁷ concentrations are raised in unstable angina. The increased risk of in-hospital coronary events and the worse prognosis associated with raised IL-6 concentrations in unstable angina support a possible role for the IL-6 family in acute coronary syndromes.⁷

Cardiotrophin 1 stimulates BNP production at a transcriptional level in vitro,⁸ suggesting that it may be involved in BNP secretion in vivo. N-BNP⁹ and cardiotrophin 1¹⁰ are present in human plasma and are raised in heart failure. No data are available on N-BNP or cardiotrophin 1 concentrations in unstable angina. We hypothesised that plasma cardiotrophin 1 and N-BNP may be raised in patients with ischaemic heart disease, particularly in unstable angina.

Methods

SUBJECTS

We compared plasma cardiotrophin 1 and N-BNP concentrations in 15 patients with unstable angina (12 male, three female; median age 71 years, range 45–86 years), 10 patients with stable angina (eight male, two female; median age 70.5 years, range 51–77 years), and 15 normal controls (five male, 10 female; median age 62 years, range 41–79 years). Patients with conditions associated with raised cardiotrophin 1 (history of or current hypertension (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 90 mm Hg), clinical or radiological evidence of left ventricular systolic dysfunction, serum creatinine > 140 µmol/l, or valvar heart disease) were excluded.

Unstable angina was defined as class IIIB of Braunwald's classification¹¹ in patients admitted to the coronary care unit of our hospital. All were treated with heparin and oral or intravenous nitrates. Stable angina was defined as a history of cardiac chest pain and positive exercise test. Patients with any increase in frequency or severity of angina in the six weeks preceding the exercise test were excluded. Controls were age matched, on no treatment, and had no evidence of ischaemic heart disease, hypertension, renal failure, or heart failure. The local ethics review committee approved the study.

BLOOD SAMPLING

Following informed consent, 20 ml of venous blood were obtained from each subject after 30–45 minutes of supine rest. In patients with unstable angina blood was drawn within 48

Department of
Medicine and
Therapeutics,
Leicester Royal
Infirmary, University
of Leicester, Leicester
LE2 7LX, UK
S Talwar
I B Squire
P F Downie
J E Davies
L L Ng

Correspondence to:
Dr Ng
email: LLN1@le.ac.uk

Accepted 20 June 2000

Table 1 Demographic details of patients with unstable and stable angina

	Unstable angina (n=15)	Stable angina (n=10)	p Value
Age (years) (median (range))	71 (45 to 86)	70.5 (51 to 77)	NS
Male/female	12/3	8/2	
History of ischaemic heart disease	11	8	
Oral nitrate	7	5	
β Blocker	3	4	
Calcium channel blocker	8	1	
Serum creatinine (μmol/l) (median (range))	98.5 (80 to 135)	96 (74 to 120)	NS
Systolic BP (mm Hg) (mean (range))	128.5 (90 to 144)	134 (110 to 165)	NS
Diastolic BP (mm Hg) (mean (range))	71 (50 to 89)	72.5 (50 to 105)	NS

BP, blood pressure.

hours of onset of chest pain and in those with stable angina before exercise testing. The blood was transferred into prechilled EDTA tubes containing 500 IU/ml of aprotinin, centrifuged, and plasma separated and stored at -70°C until assay.

IMMUNOLUMINOMETRIC ASSAYS FOR N-BNP AND CARDIOTROPHIN 1

Methods for assay of cardiostrophin 1¹⁰ and N-BNP¹² have been described previously. Within assay and between assay coefficients of variation were 3.0% and 11.2%, respectively, for N-BNP, and 6.2% and 10.3% for cardiostrophin 1. Each peptide value represents the mean of duplicate measurements determined blind to patient details.

Figure 1 Plasma concentrations of N terminal pro-brain natriuretic peptide (N-BNP) (A) and cardiostrophin 1 (CT-1) (B) in control subjects (○), patients with stable angina (▲), and patients with unstable angina (◇). The uninterrupted line is the median value.

Figure 2 Correlation between log N terminal pro-brain natriuretic peptide (N-BNP) and log cardiostrophin 1 (CT-1) in subjects with unstable angina.

STATISTICAL ANALYSIS

Statistical analyses were performed using a Minitab package (Minitab Inc, Pennsylvania, USA). Circulating N-BNP and cardiostrophin 1 concentrations were not normally distributed, and between group comparisons were made using the Mann-Whitney U test. Pearson's correlation coefficients were computed between plasma N-BNP and cardiostrophin 1. Comparisons with $p < 0.05$ were considered significant.

Results

Demographic data for the unstable angina and stable angina subjects are presented in table 1. Mean ages did not differ among the groups ($p = 0.26$, analysis of variance). N-BNP (median, range) was detected in all normal controls (150.5 fmol/ml, 104.7–236.9 fmol/ml), in patients with stable angina (169.5 fmol/ml, 105.7–399.5 fmol/ml; NS *v* controls), and in patients with unstable angina (714 fmol/ml, 177–3217 fmol/ml; $p < 0.0001$ *v* controls, $p = 0.005$ *v* stable angina) (fig 1).

Cardiostrophin 1 (median, range) was detected in all normal controls (27 fmol/ml, 6.9–54.1 fmol/ml), in patients with stable angina (73.2 fmol/ml, 41.5–102.1 fmol/ml; $p < 0.0005$ *v* controls), and in patients with unstable angina (142.5 fmol/ml, 42.2–527.4 fmol/ml; $p < 0.0001$ *v* controls; $p < 0.05$ *v* stable angina) (fig 1). Log cardiostrophin 1 correlated strongly with log N-BNP only in unstable angina ($r = 0.93$, $p < 0.0001$) (fig 2). There was no significant correlation between log cardiostrophin 1 and log N-BNP in patients with stable angina or in controls.

There were no inpatient deaths among the patients with unstable angina, six of whom underwent early coronary angiography. One of these had an angioplasty and one was referred for coronary artery surgery. In this small study we could not find any association between peptide concentrations and any of these outcomes.

Discussion

We found raised plasma concentrations of N-BNP and cardiostrophin 1 in patients with unstable angina in comparison with both control subjects and patients with stable angina, and a strong correlation between plasma

N-BNP and cardiotrophin 1 in unstable angina. Our data are in keeping with previous studies indicating raised concentrations of cytokines such as IL-6 in unstable angina.⁷

The mechanism of production of these peptides in myocardial ischaemia is unclear. Myocardial ischaemia in unstable angina may increase regional ventricular wall stretch owing to local depression of myocardial contraction. Mechanical stretch can activate the JAK/STAT pathway and may stimulate N-BNP secretion¹³ and augment the messenger RNA expression of IL-6 and cardiotrophin 1.¹⁴ This common mechanism of stimulation may explain the correlation between N-BNP and cardiotrophin 1 in unstable angina. Alternatively, cardiotrophin 1 may directly promote myocardial transcription of BNP.⁸ This cascade of events is also compatible with the small elevation of cardiotrophin 1 in stable angina. Another explanation could be different release processes in stable and unstable angina.

In man, BNP antagonises the renin-angiotensin system, causing natriuresis and contraction of plasma volume.¹⁵ In animals, cardiotrophin 1 elicits dose dependent vasodilatation that may be mediated through nitric oxide.¹⁶ Our findings with regard to N-BNP concentrations in unstable angina are analogous to those previously reported for BNP.⁶ We have observed a pronounced rise in N-BNP following acute myocardial infarction.¹⁷ Our findings with regard to cardiotrophin 1 are consistent with those in myocardial infarction¹⁸ and chronic heart failure.¹⁰ While the significance of these findings is unclear, the cytoprotective effects of cardiotrophin 1 during myocardial ischaemia may be relevant.³

LIMITATIONS

Although we studied small numbers of patients, groups were carefully defined and there was a clear separation in the concentrations of cardiotrophin 1 among the groups and in N-BNP for unstable angina. We set out to compare N-BNP and cardiotrophin 1 for the reasons discussed above. However, we have not compared cardiotrophin 1 concentrations to IL-6 or related cytokines, or N-BNP to BNP. Analysis of the relation of cardiotrophin 1 and N-BNP to markers of microinfarction such as troponin T would be of interest. Similarly the relation of peptide concentrations to echocardiographic indices of left ventricular function and to the angiographic extent of coronary artery disease remains to be established.

The influence of pharmacological treatment on concentrations of each peptide has not been addressed. We found no relation between the number of antianginal drugs and either peptide concentration. Most of the patients with unstable angina were receiving calcium antagonists but we have no direct evidence that this influenced our findings. Importantly, while cardiotrophin 1 stimulates synthesis of BNP, and while we have demonstrated correlation of circulating concentrations of the two peptides, our study does not provide direct evidence for a causal relation between cardiotrophin 1 and N-BNP concentrations. Finally, myocardial

ischaemia is a dynamic process and further studies are required to examine the profile of cardiotrophin 1 and N-BNP in both unstable and stable angina.

CONCLUSIONS

This study suggests there is elevation of a cytokine with cytoprotective properties in unstable angina. Cardiotrophin 1 or its analogues may have therapeutic potential in the protection of cardiac cells from ischaemic injury. In the absence of known inhibitors of cardiotrophin 1, it is not currently possible to investigate the consequences of inhibiting the actions of this agent in man. Further studies are now required to elucidate the pathophysiological role of the relation between cardiotrophin 1 and N-BNP in unstable angina, and its prognostic significance.

ST was supported by a Leicester Royal Infirmary Research Fellowship. Methyl acridinium esters were a gift from Drs S Woodhead and I Weeks, Molecular Light Technology Ltd, Cardiff, UK.

- 1 Pennica D, King KL, Shaw KJ, *et al.* Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. *Proc Natl Acad Sci USA* 1995;92:1142-6.
- 2 Sheng Z, Knowlton K, Chen J, *et al.* Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. *J Biol Chem* 1997;272:5783-91.
- 3 Stephanou A, Brar B, Heads R, *et al.* Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. *J Mol Cell Cardiol* 1998;30:849-55.
- 4 Yandle TG, Richards AM, Gilbert A, *et al.* Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. *J Clin Endocrinol Metab* 1993;76:832-8.
- 5 Richards AM, Nicholls MG, Yandle TG, *et al.* Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. *Circulation* 1998;97:1921-9.
- 6 Kikuta K, Yasue H, Yoshimura M, *et al.* Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. *Am Heart J* 1996;132:101-7.
- 7 Biasucci LM, Liuzzo G, Fantuzzi G, *et al.* Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. *Circulation* 1999;99:2079-84.
- 8 Kuwahara K, Saito Y, Ogawa Y, *et al.* Endothelin-1 and cardiotrophin-1 induce brain natriuretic peptide gene expression by distinct transcriptional mechanisms. *J Cardiovasc Pharmacol* 1998;31(suppl 1):S354-6.
- 9 Talwar S, Squire IB, Davies JE, *et al.* Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. *Eur Heart J* 1999;20:1736-44.
- 10 Talwar S, Downie PF, Squire IB, *et al.* An immunoluminometric assay for cardiotrophin-1: a newly identified cytokine is present in normal human plasma and is increased in heart failure. *Biochem Biophys Res Commun* 1999;261:567-71.
- 11 Braunwald E. Unstable angina. A classification. *Circulation* 1989;80:410-14.
- 12 Hughes D, Talwar S, Squire IB, *et al.* An immunoluminometric assay (ILMA) for N-terminal proBNP: development of a test for left ventricular dysfunction. *Clin Sci* 1999;96:373-80.
- 13 Nakao K, Mukoyama M, Hosoda K, *et al.* Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. *Can J Physiol Pharmacol* 1991;69:1500-6.
- 14 Pan J, Fukuda K, Saito M, *et al.* Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. *Circ Res* 1999;84:1127-36.
- 15 Hunt PJ, Espiner EA, Nicholls MG, *et al.* Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. *J Clin Endocrinol Metab* 1996;81:3871-6.
- 16 Jin H, Yang R, Ko A, *et al.* Effects of cardiotrophin-1 on haemodynamics and cardiac function in conscious rats. *Cytokine* 1998;10:19-25.
- 17 Talwar S, Squire IB, Downie PF, *et al.* Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. *Eur Heart J* In press.
- 18 Talwar S, Squire IB, Davies JE, *et al.* Plasma cardiotrophin-1 levels following myocardial infarction and the relationship with ventricular dysfunction [abstract]. *Heart* 1999; 81(suppl):115.

Commentary

Cardiotrophin 1 is a cytokine discovered 5 years ago belonging to the interleukin-6 family. Like so many cytokines, it regulates more than one cellular action. As the name suggests, cardiotrophin 1 primarily exerts growth promoting properties on cardiac myocytes and may play an especially important role in cardiac development. Both the peptide and its receptor proteins are present in normal cardiac myocytes, but it is also found in a number of other cell types. Experimental studies suggest that it is also cardioprotective, reducing the extent of ischaemia-reperfusion injury in cardiac tissue. The report by Talwar and colleagues is of inter-

est in demonstrating that plasma concentrations of cardiotrophin 1 are raised above control levels in patients with ischaemic heart disease and especially in patients with an acute coronary syndrome (unstable angina). The significance of this observation must remain speculative at present. It is presumed that the source of the plasma cardiotrophin 1 is the heart itself and it may be the case that cardiotrophin 1 is elaborated during episodes of myocardial ischaemia as a cardioprotective response in anticipation of further episodes of ischaemia.

G F BAXTER
Associate Editor

IMAGES IN CARDIOLOGY

Ruptured sinus of Valsalva aneurysm with right ventricular obstruction, quadricuspid aortic valve, and ventricular septal defect

A 41 year old man was admitted with an eight day history of exertional dyspnoea and peripheral oedema. Clinical findings were consistent with right ventricular failure. Echocardiogram showed a ruptured aneurysm of the right sinus of Valsalva protruding into the right ventricular outflow tract (fig 1A). The aneurysm induced right ventricular to pulmonary trunk obstruction with a peak Doppler velocity of 3.4 m/s. The aortic valve was quadricuspid, with mild to moderate aortic regurgitation (fig 1B). A moderate sized subarterial ventricular septal defect was seen, with left to right shunt. Both ventricles were enlarged. The findings were confirmed during surgery. Parasternal short axis echocardiogram showing quadricuspid aortic valve.

Congenital sinus of Valsalva aneurysms have been reported in association with other conotruncal malformations including bicuspid aortic valve and bulbar interventricular septal defects. To our knowledge, no case of sinus of Valsalva aneurysm with right ventricular outflow tract obstruction associated with quadricuspid aortic valve has ever been reported.

P UNGER
N PREUMONT
E STOUPEL

Figure 1 (A) Parasternal short axis view echocardiogram at the level of pulmonary artery (PA) showing the location of the aneurysmal sac (An) obstructing the right ventricular outflow tract (RVOT) immediately below the pulmonary valve (arrow). (B) Parasternal short axis view showing quadricuspid aortic valve.